<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411644</url>
  </required_header>
  <id_info>
    <org_study_id>METC 05-047</org_study_id>
    <nct_id>NCT01411644</nct_id>
  </id_info>
  <brief_title>Pheno- &amp; Genotyping POF (WHO III)</brief_title>
  <official_title>Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deventer Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focuses on the phenotyping and genotyping of women with hypergonadotropic ovarian
      dysfunction (WHO III status).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First goal of the study is to phenotype patiens with hypergonadotropic ovarian dysfunction
      (WHO III) adequately. This group includes women with premature ovarian failure (POF),
      incipient ovarian failure (IOF), poor response after ovarian hyperstimulation, early
      menopause and hypergonadotropic primary amenorrhea. The standardized phenotyping consists of
      a questionnaire focusing on reproductive, medical, and family history; ultrasonography to
      assess ovarian reserve and/or antral follicle count and obtaining an extra blood sampling
      during routine endocrine screening for genotyping.

      Phenotyping of patients presenting with ovarian dysfunction is of crucial importance when
      genotyping will be performed. The goal of this genotyping will be the identification of
      genetic factors associated with the (premature) depletion of the stock of ovarian follicles.
      It will be performed for isolated WHO III patients in an association (case-control) study for
      known candidate genes. In familial WHO III cases, genome wide linkage analysis will be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Premature Ovarian Failure (POF)</condition>
  <condition>Incipient Ovarian Failure</condition>
  <condition>Poor Response After Ovarian Hyperstimulation</condition>
  <condition>Early Menopause</condition>
  <condition>Hypergonadotropic Amenorrhea</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum and litium heparine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with WHO III status who attend the outpatient clinic of participating hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  POF; defined as secondary amenorrhea before 40 years of age and basal FSH &gt; 40 IU/L

          -  Incipient ovarian failure; defined as normo-ovulatory cycles, raised basal FSH &gt; 12
             IU/L

          -  Poor response patients; defined as less than 4 oocytes retrieved or cancellation in
             case of absent follicle growth after ovarian hyperstimulation with 300 IU
             gonadotropins or cancellation in case of absent follicle growth

          -  Women with early menopause (between 40-45 years)

          -  Hypergonadotropic primary amenorrhea

        Exclusion Criteria:

          -  Primary amenorrhea with early development disorders causing absence of ovaries and
             Swyer syndrome (XY)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart CJ Fauser, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F. Janse, MD</last_name>
    <phone>+31 88 75 55555</phone>
    <phone_ext>53629</phone_ext>
    <email>f.janse@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A. J. Goverde, MD, PhD</last_name>
    <phone>+31 88 75 55555</phone>
    <phone_ext>51445</phone_ext>
    <email>a.j.goverde@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F Janse, MD</last_name>
      <phone>+31 88 755 5555</phone>
      <phone_ext>53629</phone_ext>
      <email>f.janse@umcutrecht.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Knauff EA, Franke L, van Es MA, van den Berg LH, van der Schouw YT, Laven JS, Lambalk CB, Hoek A, Goverde AJ, Christin-Maitre S, Hsueh AJ, Wijmenga C, Fauser BC; Dutch POF Consortium. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum Reprod. 2009 Sep;24(9):2372-8. doi: 10.1093/humrep/dep197. Epub 2009 Jun 9.</citation>
    <PMID>19508998</PMID>
  </reference>
  <results_reference>
    <citation>Knauff EA, Westerveld HE, Goverde AJ, Eijkemans MJ, Valkenburg O, van Santbrink EJ, Fauser BC, van der Schouw YT. Lipid profile of women with premature ovarian failure. Menopause. 2008 Sep-Oct;15(5):919-23. doi: 10.1097/gme.0b013e31816b4509.</citation>
    <PMID>18551082</PMID>
  </results_reference>
  <results_reference>
    <citation>Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ, Themmen AP, de Jong FH, Fauser BC; Dutch Premature Ovarian Failure Consortium. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009 Mar;94(3):786-92. doi: 10.1210/jc.2008-1818. Epub 2008 Dec 9. Erratum in: J Clin Endocrinol Metab. 2010 Jan;95(1):465.</citation>
    <PMID>19066296</PMID>
  </results_reference>
  <results_reference>
    <citation>Janse F, Knauff EA, Niermeijer MF, Eijkemans MJ, Laven JS, Lambalk CB, Fauser BC, Goverde AJ; Dutch Premature Ovarian Failure Consortium. Similar phenotype characteristics comparing familial and sporadic premature ovarian failure. Menopause. 2010 Jul;17(4):758-65. doi: 10.1097/gme.0b013e3181cf8521.</citation>
    <PMID>20395876</PMID>
  </results_reference>
  <results_reference>
    <citation>Knauff EA, Blauw HM, Pearson PL, Kok K, Wijmenga C, Veldink JH, van den Berg LH, Bouchard P, Fauser BC, Franke L; Dutch Primary Ovarian Insufficiency Consortium. Copy number variants on the X chromosome in women with primary ovarian insufficiency. Fertil Steril. 2011 Apr;95(5):1584-8.e1. doi: 10.1016/j.fertnstert.2011.01.018. Epub 2011 Feb 12.</citation>
    <PMID>21316664</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Bart CJM Fauser</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>POF</keyword>
  <keyword>IOF</keyword>
  <keyword>Poor response</keyword>
  <keyword>early menopause</keyword>
  <keyword>Primary amenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

